Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit

Daix (France), April 26, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Inventiva will participate to the upcoming 7th Annual Truist Securities Life Sciences Summit, being held virtually on May 4-5, 2021. During the event, members of the Company’s leadership will engage in 1×1 investor meetings. The event details are as follows: Format: One-on-one investor meetingsParticipants: Frédéric Cren, Chairman, CEO and cofounder of Inventiva, and David Nikodem, Vice President of US Operations of InventivaDate: Tuesday-Wednesday, May 4-5, 2021Time: 8:00 am – 5:00 pm (ET) / 2:00 pm – 11:00 pm (CET) About Inventiva  Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020. In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts InventivaFrédéric CrenChairman & [email protected]+33 3 80 44 75 00Brunswick GroupYannick Tetzlaff / Tristan Roquet Montegon / Aude LepreuxMedia [email protected]+33 1 53 96 83 83Westwicke, an ICR CompanyPatricia L. BankInvestor [email protected]+1 415 513-1284
Attachment

Inventiva – PR – 7th Annual Truist Securities Life Science Summit – EN – 26 04 2021